
CANF Stock Forecast & Price Target
CANF Analyst Ratings
Bulls say
Can Fite Biopharma Ltd is positioned for strong financial growth, with projections indicating risk-adjusted global sales reaching approximately $19.7 million in 2031 for its drug candidate Namodenoson, projected to enter the market in early 2028. Additionally, from 2027 to 2031, risk-adjusted product revenues are expected to rise significantly from around $3 million to $126 million, showcasing the potential for substantial revenue growth as the company advances its pipeline. The recent clinical successes and ongoing studies of its drug candidates, especially with the favorable outcomes for piclidenoson and the compelling case of Namodenoson's impact on advanced liver cancer, further enhance the overall positive outlook for Can Fite’s market position.
Bears say
Can Fite Biopharma Ltd has encountered significant challenges that negatively impact its financial outlook, including the potential inability to successfully commercialize its products and lower-than-expected market penetration, which could hinder revenue projections. The company recorded a net loss of $4.9 million in the first half of 2025 and anticipates a total net loss of $10 million for the year, leading to an adjustment in its financial model which incorporates potential dilution and reduces the price target from $11.0 to $4.0. Additionally, delays in obtaining regulatory approvals, patient enrollment in clinical trials, and management's ability to protect intellectual property pose further risks to Can-Fite's commercial viability and growth prospects.
This aggregate rating is based on analysts' research of Can-Fite BioPharma Ltd. and is not a guaranteed prediction by Public.com or investment advice.
CANF Analyst Forecast & Price Prediction
Start investing in CANF
Order type
Buy in
Order amount
Est. shares
0 shares